Effect of high-dose Omega 3 on lipid profile and inflammatory markers in chronic hemodialysis children.
Atherosclerosis, cardiovascular diseases (CVDs), and inflammation are important problems in chronic kidney disease (CKD) patients on chronic hemodialysis (HD). Prevention of CKD patients of CVD can lower the mortality rate in them. Omega 3 may help in the treatment of inflammation and lipid abnormalities in end-stage renal disease (ESRD) patients on chronic HD. This study aimed to evaluate the effect of high-dose Omega 3 on lipid profile and inflammatory markers in ESRD children on chronic HD. This clinical trial was conducted on 49 ESRD children on chronic HD selected from pediatric HD unit of Menoufia University Hospital. The study was conducted for a period of three months. The selected children were supplemented with 2000-mg Omega 3 tablets daily; lipid profile and inflammatory markers were assessed at the beginning and at the end of the study. Supplementation with high-dose Omega 3 resulted in a highly statistically significant decrease in total cholesterol, triglyceride, low-density lipoprotein, interleukin-6, C- reactive protein levels and a highly statistically significant increase in high-density lipoprotein (P <0.001). The differences between hemoglobin, platelets, iron profile, parathyroid hormone, albumin, phosphorus, calcium, potassium, sodium, and efficiency of dialysis before and after Omega 3 supplementation were not statistically significant (P >0.05). Supplementation with highdose Omega 3 caused significant improvement in lipid profile and inflammatory markers of children on chronic HD.